Contract

Corporate Governance and Contracts Manager/Paralegal

Korro Bio

Korro Bio

51-200 employees

RNA editing-based therapeutics discovery and development

Compensation Overview

$36 - $48/hr

+ Equity

Cambridge, MA, USA

Hybrid

Hybrid role requires onsite 2-3 days per week.

Category
Legal & Compliance

Get referred to Korro Bio

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in law, business administration, finance, life sciences, or related field.
  • At least 5 years of experience as a corporate governance, contracts, or corporate paralegal/manager in a law firm or in-house legal department.
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint, Outlook). Strong attention to detail and document management capabilities.
  • Experience and willingness to leverage AI optimization tools (Claude) to facilitate workflows.
  • Comfortable learning new software platforms and contract lifecycle management systems (CLM).
  • Understanding of legal terminology and document structures.
  • Excellent written and verbal communication skills.
  • Strong project management skills; flexible and capable of managing and prioritizing multiple duties and projects within specified time frames.
  • Self-motivated, flexible, collaborative, eager to learn, and interested in working on a wide range of legal, contracts, governance and compliance matters.
  • High level of discretion and ability to handle confidential information.
  • Analytical mindset with problem-solving capabilities
  • Ability to work independently and as part of a collaborative team.
  • Ability to be onsite 2-3 days per week.
Responsibilities
  • Assist with contract intake, tracking, and database management using contract lifecycle management (CLM) systems.
  • Review and revise contracts for products and services.
  • Support contract review processes by organizing documents, creating summaries, and maintaining version control.
  • Help prepare standard contract templates and addendums for routine agreements.
  • Coordinate contract execution processes, including e-signature collection of appropriate signatories and final document distribution.
  • Proofread, edit, and fact-check contract documents for completion, consistency, and accuracy.
  • Evaluate opportunities for streamlining current contract lifecycle management processes.
  • Assist with reporting renewals and terminations of executed contracts.
  • Create, run, and distribute contract information reports.
  • Escalate deviations to Contracts Counsel.
  • Maintain contract repositories and ensure proper filing and accessibility of executed agreements.
  • Assist with board meeting preparation by organizing materials, formatting presentations, and creating meeting packets.
  • Support maintenance of corporate records, including board resolutions, committee charters, and governance policies.
  • Support SEC filings, including 10-K, 10-Q, 8-K, and proxy statement, including assistance with preparation of disclosures and tables, maintenance of filings calendars, preparation and management of D&O questionnaires, and preparation and filing of Section 16 reports.
  • Help track and monitor compliance deadlines for corporate filings and regulatory requirements.
  • Assist with shareholder communications and equity administration tasks.
  • Support preparation of governance-related reports and summaries for leadership.
  • Help develop, streamline, implement and maintain processes and policies across the organization, including those related to securities reporting, compliance, equity administration, and contracts.
  • Support strategic transactions, including due diligence, data room administration, document preparation, and post-closing administration.
  • Other tasks and duties as assigned.
Desired Qualifications
  • Paralegal certificate or coursework preferred.
  • Experience as a corporate governance, contracts, or corporate paralegal/manager in a law firm or in-house legal department at a biotech or life sciences company preferred.

Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2019

Get referred to Korro Bio

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $85M PIPE in 2025 extends cash runway through H2 2028.
  • Novo Nordisk partnership develops cardiometabolic candidates since Sept 2024.
  • KRRO-121 advances for urea cycle disorders and hepatic encephalopathy.

What critics are saying

  • KRRO-110 trial failed functional protein levels, causing 80% stock drop.
  • Beam Therapeutics' base editing outpaces Korro in AATD liver delivery.
  • Intellia CRISPR AATD enters Phase 1 with 50% NHP protein correction.

What makes Korro Bio unique

  • OPERA platform co-opts endogenous ADAR for precise single-base RNA edits.
  • CHORD oligonucleotides enable high specificity without off-target DNA risks.
  • Targets liver diseases like AATD using precedented manufacturing and delivery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-1%

2 year growth

0%
Maeil Business Newspaper
Mar 9th, 2026
Korro Bio raises $85M PIPE to fund operations through H2 2028

Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.

Investing.com
Mar 9th, 2026
Korro Bio raises $85 million in private equity financing By Investing.com

Korro Bio raises $85 million in private equity financing

Stock Titan
Jan 7th, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Investing.com
Oct 16th, 2024
KRRO stock soars to 52-week high, touches $98 amid robust gains

In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.

BioSpace
Sep 16th, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.